Kathryn Hayashi
Vorstandsvorsitzender bei TRIUMF Innovations, Inc.
Profil
Kathryn Hayashi is currently the CEO of TRIUMF Innovations, Inc., Director of ARTMS, Inc., and a Board of Director member for Nimbus Synergies, Inc. She previously worked as a Director for Sitka Biopharma, Inc., Zucara Therapeutics, Inc., and as the CFO for The Centre for Drug Research & Development.
Hayashi received an undergraduate degree from the University of British Columbia in 2000.
Aktive Positionen von Kathryn Hayashi
| Unternehmen | Position | Beginn |
|---|---|---|
ARTMS, Inc.
 ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | Direktor/Vorstandsmitglied | 28.03.2018 |
Centre For Commercialization of Cancer Immunotherapy
 Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | Direktor/Vorstandsmitglied | - |
Nimbus Synergies, Inc.
 Nimbus Synergies, Inc. Investment ManagersFinance Nimbus Synergies Inc (Nimbus Synergies) is a venture capital firm founded in 2017 by Jason Robertson. The firm is headquartered in British Columbia, Canada. | Direktor/Vorstandsmitglied | 01.09.2017 |
Nimbus Synergies, Inc.
Nimbus Synergies, Inc. Investment ManagersFinance Nimbus Synergies Inc (Nimbus Synergies) is a venture capital firm founded in 2017 by Jason Robertson. The firm is headquartered in British Columbia, Canada. | Direktor/Vorstandsmitglied | - |
TRIUMF Innovations, Inc.
 TRIUMF Innovations, Inc. Information Technology ServicesTechnology Services TRIUMF Innovations, Inc. is the business interface and commercialization arm of TRIUMF, Canada's particle accelerator center. The private company is based in Vancouver, Canada. The Canadian company connects TRIUMF to the private sector through industry partnerships, licensing, and company creation. Kathryn Hayashi has been the CEO of the company since 2017. | Vorstandsvorsitzender | 01.02.2017 |
Ehemalige bekannte Positionen von Kathryn Hayashi
| Unternehmen | Position | Ende |
|---|---|---|
Sitka Biopharma, Inc.
 Sitka Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sitka Biopharma, Inc. develops novel polymer platform technology that improves drug absorption for cancer treatments. The company was founded by Michael Parr in 2013 and is headquartered in Vancouver, the United Kingdom. | Direktor/Vorstandsmitglied | 01.01.2017 |
Zucara Therapeutics, Inc.
 Zucara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Zucara Therapeutics, Inc. develops and manufactures drug therapy for hypoglycemia in type 1 diabetes people. The company is headquartered in Toronto, Canada. | Direktor/Vorstandsmitglied | 01.01.2017 |
The Centre for Drug Research & Development
 The Centre for Drug Research & Development Miscellaneous Commercial ServicesCommercial Services Center for Drug Research & Development operates as a drug development and commercialization company. The firm provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. The company was founded in 2007 and is headquartered in Vancouver, Canada. | Finanzdirektor/CFO | 01.01.2017 |
Ausbildung von Kathryn Hayashi
| University of British Columbia | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
The Centre for Drug Research & Development
The Centre for Drug Research & Development Miscellaneous Commercial ServicesCommercial Services Center for Drug Research & Development operates as a drug development and commercialization company. The firm provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. The company was founded in 2007 and is headquartered in Vancouver, Canada. | Commercial Services |
Sitka Biopharma, Inc.
Sitka Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sitka Biopharma, Inc. develops novel polymer platform technology that improves drug absorption for cancer treatments. The company was founded by Michael Parr in 2013 and is headquartered in Vancouver, the United Kingdom. | Health Technology |
ARTMS, Inc.
ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | Health Technology |
Nimbus Synergies, Inc.
Nimbus Synergies, Inc. Investment ManagersFinance Nimbus Synergies Inc (Nimbus Synergies) is a venture capital firm founded in 2017 by Jason Robertson. The firm is headquartered in British Columbia, Canada. | Finance |
Zucara Therapeutics, Inc.
Zucara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Zucara Therapeutics, Inc. develops and manufactures drug therapy for hypoglycemia in type 1 diabetes people. The company is headquartered in Toronto, Canada. | Health Technology |
TRIUMF Innovations, Inc.
TRIUMF Innovations, Inc. Information Technology ServicesTechnology Services TRIUMF Innovations, Inc. is the business interface and commercialization arm of TRIUMF, Canada's particle accelerator center. The private company is based in Vancouver, Canada. The Canadian company connects TRIUMF to the private sector through industry partnerships, licensing, and company creation. Kathryn Hayashi has been the CEO of the company since 2017. | Technology Services |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. |
